ArticleBMC cancer2018
A molecular and staging model predicts survival in patients with resected non-small cell lung cancer.
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- The impact of hydromorphone combined with ropivacaine in serratus anterior plane block on postoperative pain in patients undergoing video-assisted thoracoscopic pulmonary lobectomy: a randomized, double-blind clinical trial.BMC anesthesiology · 2025Trial
- Radiomics-Clinical AI Model with Probability Weighted Strategy for Prognosis Prediction in Non-Small Cell Lung Cancer.Biomedicines · 2023Article
- Establishing a metastasis-related diagnosis and prognosis model for lung adenocarcinoma through CRISPR library and TCGA database.Journal of cancer research and clinical oncology · 2023Article
- Integrative bioinformatics approaches to establish potential prognostic immune-related genes signature and drugs in the non-small cell lung cancer microenvironment.Frontiers in pharmacology · 2023Article
- Preoperative Serum Triglyceride to High-Density Lipoprotein Cholesterol Ratio Can Predict Prognosis in Non-Small Cell Lung Cancer: A Multicenter Retrospective Cohort Study.Current oncology (Toronto, Ont.) · 2022Article
- Prognostic impact of an integrative analysis of [EJNMMI research · 2022Article
- Identification of key candidate genes associated with prognosis of lung adenocarcinoma by integrated bioinformatical analysis.Translational cancer research · 2020Article
- TNNT2 as a potential biomarker for the progression and prognosis of colorectal cancer.Oncology reports · 2020Article
- Prognostic value of serum high-density lipoprotein cholesterol elevation in nonsmall cell lung cancer patients receiving radical surgery.Clinical and translational medicine · 2020Article
- Ceramide Pathway Regulators Predict Clinical Prognostic Risk and Affect the Tumor Immune Microenvironment in Lung Adenocarcinoma.Frontiers in oncology · 2020Article
- Construction of a Prognostic Immune Signature for Squamous-Cell Lung Cancer to Predict Survival.Frontiers in immunology · 2020Article
- Establishment and Validation of a Nomogram Based on Negative Lymph Nodes to Predict Survival in Postoperative Patients with non-Small Cell Lung Cancer.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe current TNM staging system is far from perfect in predicting the survival of individual non-small cell lung cancer (NSCLC) patients. In this study, we aim to combine clinical variables and molecular biomarkers to develop a prognostic model for patients with NSCLC.
methodsCandidate molecular biomarkers were extracted from the Gene Expression Omnibus (GEO), and Cox regression analysis was performed to determine significant prognostic factors. The survival prediction model was constructed based on multivariable Cox regression analysis in a cohort of 152 NSCLC patients. The predictive performance of the model was assessed by the Area under the Receiver Operating Characteristic Curve (AUC) and Kaplan-Meier survival analysis.
resultsThe survival prediction model consisting of two genes (TPX2 and MMP12) and two clinicopathological factors (tumor stage and grade) was developed. The patients could be divided into either high-risk group or low-risk group. Both disease-free survival and overall survival were significantly different among the diverse groups (P < 0.05). The AUC of the prognostic model was higher than that of the TNM staging system for predicting survival.
conclusionsWe developed a novel prognostic model which can accurately predict outcomes for patients with NSCLC after surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.